Neuroimaging in pre-motor Parkinson's disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The process of neurodegeneration in Parkinson's disease begins long before the onset of clinical motor symptoms, resulting in substantial cell loss by the time a diagnosis can be made. The period between the onset of neurodegeneration and the development of motoric disease would be the ideal time to intervene with disease modifying therapies. This pre-motor phase can last many years, but the lack of a specific clinical phenotype means that objective biomarkers are needed to reliably detect prodromal disease. In recent years, recognition that patients with REM sleep behaviour disorder (RBD) are at particularly high risk of future parkinsonism has enabled the development of large prodromal cohorts in which to investigate novel biomarkers, and neuroimaging has generated some of the most promising results to date. Here we review investigations undertaken in RBD and other pre-clinical cohorts, including modalities that are well established in clinical Parkinson's as well as novel imaging methods. Techniques such as high resolution MRI of the substantia nigra and functional imaging of Parkinsonian brain networks have great potential to facilitate early diagnosis. Further longitudinal studies will establish their true value in quantifying prodromal neurodegeneration and predicting future Parkinson's.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Correspondence of the brain's functional architecture during activation and rest
Smith, S. M., Fox, P. T., Miller, K. L., Glahn, D. C., Fox, P. M., Mackay, C. E., Filippini, N., Watkins, K. E., Toro, R., Laird, A. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905267106 · Cited by 5,150
Self-citationAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Investigations into resting-state connectivity using independent component analysis
Beckmann, C. F., DeLuca, M., Devlin, J. T., & Smith, S. M. (2005) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1634 · Cited by 3,398
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · cited 1×
“Heterozygous GBA mutations occur in around 4–7% of sporadic cases and are 5 times more common in PD patients than in controls (Sidransky et al., 2009).”
Doty, R. L., Shaman, P., & Dann, M. (1984) · Physiology & Behavior · doi:10.1016/0031-9384(84)90269-5 · Cited by 1,854
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Self-citationAccuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870 · cited 2×
“…has led to problems in the study of other neurodegenerative diseases, particularly in the context of clinical trial design (Karran and Hardy, 2014), and given the fallibility of clinical diagnosis in up to 20% of Parkinson's disease cases (Rizzo et al., 2016b) this is an important consideration.”
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.009 · Cited by 814
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Cited by
Update of the MDS research criteria for prodromal Parkinson's disease
Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C., Postuma, R. B., & the MDS Task Force on the Definition of Parkinson's Disease (2019) · Movement Disorders · doi:10.1002/mds.27802 · Cited by 768
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Impaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
Gupta, R., Kumari, S., Senapati, A., Ambasta, R. K., & Kumar, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102013 · Cited by 134
Metadata
- Authors
- Barber, T. R., Klein, J. C., Mackay, C. E., & Hu, M. T. M.
- Venue
- NeuroImage: Clinical
- Publisher
- Elsevier BV
- Published
- 2017
- Volume
- 15
- Pages
- 215-227
- ISSN
- 2213-1582 (ISSN-L)
- OpenAlex
- W2606337386
- Cited by
- 84
- References
- 15
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroimaging in pre-motor Parkinson's disease. https://app.cochat.ai/papers/10.1016/j.nicl.2017.04.011
- The paper
- Barber, T. R., Klein, J. C., Mackay, C. E., & Hu, M. T. M. (2017). Neuroimaging in pre-motor Parkinson's disease. NeuroImage: Clinical. https://doi.org/10.1016/j.nicl.2017.04.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.